Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA

Breaking News Melanoma Research

October 1, 2021 Kristi Rosa REPOST from OncLive The European Medicines Agency has validated its marketing authorization application for the fixed-dose combination of relatlimab and nivolumab in the frontline treatment of adult and pediatric patients with advanced melanoma. Jonathan Cheng The European Medicines Agency has validated its marketing authorization application for the fixed-dose combination of relatlimab and nivolumab (Opdivo) in … Read More